Navigation Links
Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO

opment and commercialization agreement.

For additional information on Kosan Biosciences, please visit the company's website at http://www.kosan.com.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 (the "Act"). Such forward-looking statements include but are not limited to the further development and potential safety, efficacy, commercialization, and other characteristics of Kosan's Hsp90 product candidates; and initiations of clinical trials and the timing thereof. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. There are a number of important factors that could cause the results of Kosan to differ materially from those indicated by these forward-looking statements, including, among others, risks related to the development of Kosan's Hsp90 product candidates, including the risk that studies may not demonstrate safety and efficacy sufficient to initiate clinical trials, continue clinical development, obtain the requisite regulatory approvals or to result in a marketable product; and other risks detailed from time to time in the Company's SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2007 and other periodic filings with the SEC. Kosan does not undertake any obligation to update forward-looking statements.

Velcade(R) (bortezomib) is a registered trademark of Millennium Pharmaceuticals, Inc.

Herceptin(R) (trastuzumab) is a registered trademark of Genentech, Inc.

Taxol(R) is a registered trademark of Bristol-Myers Squibb Company.

CONTACT: Jane Green, VP of Corporate Communications of Kosan BiosciencesIncorporated, +1-510-731-5335, mobile, +1-415-652-4819, green@kosan.com

Web
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
2. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
3. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
4. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
5. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
6. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
7. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
Post Your Comments:
(Date:1/15/2014)... Jan. 15, 2014 Tegra Medical is very pleased to ... as its new Chief Executive Officer.  Mark was promoted from ... has overseen the company,s four facilities in Massachusetts ... Mr. King joined Tegra Medical in 2012 with 20+ years ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... & Forecast – Worldwide Analysis ... Pump Market Analysis ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... IOMI ) today announced that Stanley C. Erck, the ... Acumen BioFin,Rodman & Renshaw 9th Annual Healthcare Conference in ... will begin at 9:10 a.m. Eastern,Time in the Kennedy ... Mr. Erck,s presentation will focus on Iomai,s portfolio of ...
... Exelixis, Inc. (Nasdaq:,EXEL) today presented data from ... with albuminuria due to diabetic nephropathy. XL784 is ... enzymes that may,play a role in the pathogenesis ... presented during a poster session (Abstract/Poster PO1030) at,the ...
Cached Medicine Technology:Iomai CEO to Speak at Acumen BioFin Rodman & Renshaw Annual Healthcare Conference on Monday, Nov. 5 2Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference 2Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference 3Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference 4
(Date:4/17/2014)... many as 10 million older Americans suffer from depression, ... , However, new research a project that followed ... six years found that Internet use among the ... than 30 percent. , "That,s a very strong effect," ... telecommunication, information studies and media who led the project. ...
(Date:4/17/2014)... CHICAGO, IL, April 17, 2014-- Colic affects about one ... accounts for numerous pediatric visits during the first several ... of colic symptoms was showing promise; however, the April ... (BMJ2014;348:g2107; Sung, Valerie) reported on a study, "Probiotics ... probiotic L reuteri for infant colic ...
(Date:4/17/2014)... Boston University School of Medicine (BUSM) have discovered ... in an experimental model. The findings, reported in ... Abuse , may lead to more effective treatments ... one of the leading causes of illness and ... economic impact by limiting the productivity of workers ...
(Date:4/17/2014)... An international team led by researchers at UC Davis ... plays a key role in cell division, also boosts ... the first time the complex has been shown to ... B1/Cdk1 an excellent target to control cellular energy production, ... was published online today in the journal Developmental ...
(Date:4/17/2014)... led by Cesar A. Arias, M.D., Ph.D., at The ... has identified a new superbug that caused a bloodstream ... the April 17 issue of The New England ... part of a class of highly-resistant bacteria known as ... a major cause of hospital and community-associated infections. The ...
Breaking Medicine News(10 mins):Health News:Internet use can help ward off depression among elderly 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:New MRSA superbug emerges in Brazil 2
... Cystitis Epidemiology (RICE) study estimates prevalence of 3 to ... 13 Three to eight million women in the ... newly released prevalence number, presented at the 2009 American ... to 6 percent of all U.S. women. This ...
... 13 Cyberonics, Inc. (Nasdaq: CYBX ) today ... fourth quarter and fiscal year ended April 24, 2009 on ... company will conduct a conference call to discuss those results ... Fourth Quarter and FY2009 Results Conference Call Instructions ...
... Fixed-dose combination offers a convenient option that may ... pressure goals while decreasing patient pill burden(1)PARSIPPANY, N.J., ... that the United States Food and Drug Administration ... and olmesartan medoxomil) as initial or ,first-line, therapy ...
... Surgical Information Systems (SIS) successfully completed the ... the Healthcare Enterprise (IHE) Connectathon, and participated ... Society (HIMSS) Interoperability Showcase in Chicago.(Logo: ... )The Connectathon is the healthcare IT industry,s ...
... Watts Enables Physicians to Melt and Remove Larger Areas ... May 13 Cynosure, Inc. ... manufacturer of a broad array of light-based aesthetic treatment ... the latest and most powerful advance in the company,s ...
... experts say , , WEDNESDAY, May 13 (HealthDay News) -- ... normal-weight co-workers, says a U.S. study. , Researchers surveyed ... effectiveness and impairment of daily activities. The results showed ... diabetes lost 11 percent to 15 percent of work ...
Cached Medicine News:Health News:Prevalence of Interstitial Cystitis in U.S. Much Larger Than Previously Believed 2Health News:Cyberonics Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2009 Financial Results 2Health News:AZOR(R) Receives FDA Approval as First-Line Treatment for High Blood Pressure 2Health News:AZOR(R) Receives FDA Approval as First-Line Treatment for High Blood Pressure 3Health News:AZOR(R) Receives FDA Approval as First-Line Treatment for High Blood Pressure 4Health News:AZOR(R) Receives FDA Approval as First-Line Treatment for High Blood Pressure 5Health News:AZOR(R) Receives FDA Approval as First-Line Treatment for High Blood Pressure 6Health News:SIS Completes IHE Connectathon, Participates in HIMSS Interoperability Showcase 2Health News:Cynosure Enhances Industry-Leading Smartlipo Laser Lipolysis Workstation with Increased Energy and Intelligent Temperature Sensing 2Health News:Cynosure Enhances Industry-Leading Smartlipo Laser Lipolysis Workstation with Increased Energy and Intelligent Temperature Sensing 3Health News:Cynosure Enhances Industry-Leading Smartlipo Laser Lipolysis Workstation with Increased Energy and Intelligent Temperature Sensing 4Health News:Cynosure Enhances Industry-Leading Smartlipo Laser Lipolysis Workstation with Increased Energy and Intelligent Temperature Sensing 5Health News:Productivity Takes a Hit From Obesity, Diabetes 2
... developed over Guidants 20-year history, the VOYAGER ... for successful treatment outcomes. It combines a ... a lower profile shaft,more flexible markers, and ... cross tight and tortuous anatomy with even ...
... technology developed over Guidants 20-year history, the ... foundation for successful treatment outcomes. It combines ... with a lower profile shaft,more flexible markers, ... can cross tight and tortuous anatomy with ...
Test for AFP...
Enzyme Immunoassay for the Quantitative Measurement of Ovarian Cancer Antigen CA-125 in Human Serum...
Medicine Products: